727 C Pill — BROWN OVAL, 13mm — Glipizide

No photo available

Imprint	727 / C
Colour	BROWN
Shape	OVAL
Size	13
Strength	—
Dosage form	Tablet
Manufacturer	CARACO PHARMACEUTICAL LABORATORIES, LTD.
NDC	57664-727
Schedule	—
Availability	—
Ingredients	—

What does this imprint mean?

The imprint "727 C" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.

Active ingredient

Glipizide

Uses and warnings

Key Warnings: - Hypoglycemia: "All sulfonylurea drugs, including glipizide extended-release tablets, are capable of producing severe hypoglycemia." Risk increases with combination therapy. Higher risk in elderly, renally impaired, and debilitated patients. - Hemolytic Anemia: Can occur in glucose-6-phosphate dehydrogenase (G6PD) deficient patients; avoid use in this population. - Cardiovascular Mortality: Based on historical UGDP study, oral hypoglycemic drugs associated with increased cardiovascular mortality compared to diet alone. - Gastrointestinal Obstruction: Avoid in patients with severe preexisting gastrointestinal narrowing due to extended-release formulation.

"Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." Not for type 1 diabetes or diabetic ketoacidosis.

Read the full drug profile →